证券研究报告 2024 年 7 月 22 日 湘财证券研究所 行业研究 公用事业行业周报 三中全会进一步全面深化改革,公用事业市场化改革加速 相关研究: 《三峡水库来水大增,大水电绿证获发 彰显水电环境价值》 2024.07.16 《发电行业碳配额方案发布,延续适度 收紧趋势》 2024.07.09 行业评级:增持 近十二个月行业表现 | --- | --- | --- | --- | |----------|--------|--------|----------| | % | 1 个月 | 3 个月 | 12 个月 | | 相对收益 | 1 | 5 | 13 | | 绝对收益 | 2 | 4 | 5 | | | | | 300 相比 | 分析师:孙菲 证书编号:S0500524010002 Tel:(8621) 50293587 Email:sf06902@xcsc.com 地址:上海市浦东新区银城路88号 中国人寿金融中心10楼 核心要点: ❑ 本周公用事业(申万)上涨 0.07%,跑输沪深 300 指数 1.85 个百分点 截至 2024 年 7 月 19 日,本周沪深 300 上涨 1.92%,创业 ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expected investment return that exceeds the market benchmark by more than 15% over the next 6-12 months [9]. Core Insights - The company focuses on the traditional Chinese medicine industry, with a strong emphasis on innovative research and development of proprietary Chinese medicines, while also expanding into chemical pharmaceuticals and the health industry [4][5]. - The company's unique competitive advantage lies in its research on the "Luo Disease Theory," which has been integrated into its drug development and marketing strategies, establishing a comprehensive operational model [5][11]. - The company has a robust product pipeline, with proprietary medicines covering various therapeutic areas, including cardiovascular, respiratory, digestive, neurological, and oncology [7][11]. Summary by Sections Company Overview - The company is primarily engaged in the research, production, and sales of patented innovative Chinese medicines, while also developing chemical pharmaceuticals and health products [4]. - It has received numerous national and provincial awards for its research efforts, including one first-class and four second-class National Science and Technology Progress Awards [4]. Research and Development - The company employs a multi-channel R&D approach, focusing on compound, component, and single-entity Chinese medicines, guided by clinical practices and theoretical hypotheses [4]. - It has established a clinical research and transformation platform based on the Luo Disease Theory, contributing to over 40 evidence-based studies published in international medical journals [5][6]. Product Portfolio - The company has developed a series of proprietary medicines targeting major diseases, with 22 unique traditional Chinese medicines across eight categories, achieving leading positions in the cardiovascular and respiratory disease markets [7][8]. - Key products include Tongxinluo capsules and Lianhua Qingwen capsules, which have shown significant sales growth in public medical institutions and online pharmacies [7][8]. Financial Performance and Projections - The company experienced a decline in revenue and net profit in 2023, with a projected recovery starting in 2024 as high base effects diminish [9][11]. - Revenue is expected to reach CNY 10.11 billion in 2024, with a growth forecast of 13.6% in 2025 and 17.7% in 2026 [12]. Market Position and Strategy - The company aims to leverage its unique theoretical framework and strong R&D capabilities to enhance its market position and drive future growth [11]. - A new brand marketing strategy is anticipated to synergize the company's theoretical, product, and corporate brands, further boosting sales [11].

证券研究报告 2024 年 07 月 22 日 湘财证券研究所 行业研究 国防军工行业周报 二十届三中全会《决定》公布:持续深化国防和军队改革 ——国防军工行业周报(07.15~07.19) 相关研究: 1.《20240528湘财证券-国防军工 行业:eVTOL起降场技术要求团 体标准发布,助力低空经济加速 发展》2024.05.28 2.《20240625湘财证券-国防军工 行业-亿航智能与温州市文成县 政府达成合作,看好低空经济长 期发展》2024.06.25 行业评级:增持 近十二个月行业表现 国防军工(申万) 沪深300 -40% -30% -20% -10% 0% 10% 23/07 23/09 23/11 24/01 24/03 24/05 | --- | --- | --- | --- | |----------|--------|--------|----------| | % | 1 个月 | 3 个月 | 12 个月 | | 相对收益 | | | | | 绝对收益 | | | | | | | | 300 相比 | 分析师:轩鹏程 证书编号:S0500521070003 Tel:(8621) ...

证券研究报告 2024 年 07 月 22 日 湘财证券研究所 行业研究 银行业事件点评 LPR 全面下调,降息幅度符合预期 相关研究: 而致远》 2023.12.23 2.《地产融资支持加强,助力缓释 资产风险》 2024.01.31 3.《中期策略:预期渐收敛,配置 价值延续》 2024.06.21 动结构性工具落地》 2024.07.03 优化》 2024.07.15 % 1 个月 3 个月 12 个月 相对收益 3.55 3.07 22.50 绝对收益 3.37 2.21 14.30 分析师:郭怡萍 证书编号:S0500523080002 Tel:(8621) 50295327 Email:guoyp@xcsc.com 事件: 7 月 22 日,7 天逆回购利率下调 10 BP 至 1.7%,1 年期和 5 年期 LPR 同时 下调 10 BP。当前,1 年期 LPR 为 3.35%,5 年期 LPR 为 3.85%。 1.《2024年度策略:量质均衡,进 核心要点: LPR 全面下调,降息幅度符合预期 本轮 LPR 降息与上次调整一样,是在 MLF 利率不动的情况下单独实施。 今年 2 月,LPR ...

证券研究报告 2024 年 07 月 22 日 湘财证券研究所 公司研究 奥特维(688516) 业绩维持高速增长,新领域逐渐放量 相关研究: 1.《20240527湘财证券-机械行业: 4月我国新增光伏装机14.4GW,同 比下降1.9%》 2.《20240702湘财证券-机械行业: 6月我国PMI为49.5%,环比持平》 公司评级:买入(首次覆盖) 近十二个月公司表现 奥特维 沪深300 -60% -40% -20% 0% 20% 23/07 23/09 23/11 24/01 24/03 24/05 24/07 % 1 个月 3 个月 12 个月 相对收益 -12.2 -40.0 -44.5 绝对收益 -12.6 -41.2 -53.4 注:相对收益与沪深 300 相比 分析师:轩鹏程 证书编号:S0500521070003 Tel:(8621) 50295321 Email:xuanpc@xcsc.com 地址:上海市浦东新区银城路 88 号 中国人寿金融中心 10 楼 敬请阅读末页之重要声明 1 核心要点: ❑ 公司为我国光伏组件设备龙头,近年来业绩保持高速增长 无锡奥特维科技股份有限公司成立于 2 ...

证券研究报告 2024 年 07 月 22 日 湘财证券研究所 行业研究 疫苗行业周报 三中全会再提技术创新,强技术性疫苗行业迎更大发展空间 核心要点: ❑ 市场表现:上周疫苗上涨 4.42%,医药板块普涨,疫苗涨幅居首 上周(2024.07.15-2024.07.19)医药生物报收 6740.49 点,上涨 1.29%;原料药 报收 8456.1 点,上涨 2.16%;化学制剂报收 6349.36 点,上涨 0.16%;中药Ⅲ 报收 6281.96 点,上涨 1.91%;血液制品报收 11333.89 点,上涨 4.12%;疫苗 报收 12572.16 点,上涨 4.42%;其他生物制品报收 8241.78 点,上涨 0.53%; 医疗设备报收 10035.94 点,上涨 2.07%;医疗耗材报收 4872.48 点,下跌 0.41%; 体外诊断报收 7151.17 点,上涨 0.88%;医药流通报收 2612.88 点,上涨 1.59%; 线下药店报收 11562.81 点,上涨 0.68%;医疗研发外包报收 6588.79 点,上涨 1.52%;医院报收 4007.94 点,上涨 0.72%。医药板块普 ...

证券研究报告 2024 年 7 月 20 日 湘财证券研究所 公司研究 华能国际(600011.SH) 新能源业务增长稳定电量表现,煤价中枢下行持续优化成本 相关研究: 《发电行业碳配额方案发布,延续适 度收紧趋势》 2024.07.09 《国家绿证核发交易系统启用,绿电 交易市场有望扩容》 2024.07.01 公司评级:增持 近十二个月公司表现 | --- | --- | --- | --- | |----------|--------|--------|----------| | % | 1 个月 | 3 个月 | 12 个月 | | 相对收益 | -1 | -6 | 5 | | 绝对收益 | -1 | -7 | -3 | | | | | 300 相比 | 分析师:孙菲 证书编号:S0500524010002 Tel:(8621) 50293587 Email:sf06902@xcsc.com 地址:上海市浦东新区银城路88号 中国人寿金融中心10楼 核心要点: ❑ 事件 7 月 16 日,华能国际发布 2024 年上半年上网电量完成情况。2024 年上半 年,公司中国境内各运行电厂按合并报表口径完成上 ...

Investment Rating - The report assigns a rating of "Accumulate" to the company, indicating a potential investment return exceeding the market benchmark index by 5% to 15% over the next 6-12 months [20][29]. Core Insights - The company has initiated a marketing revitalization plan to adapt to changes in the international environment, slow domestic consumption recovery, and the presence of numerous market products. This plan involves establishing a new digital marketing system across four dimensions: brand, product, channel, and organization [1]. - The company focuses on premium traditional Chinese medicine, particularly on products like Ganoderma lucidum and Dendrobium, and has developed a comprehensive supply chain that ensures product quality and innovation [18][31]. - The company has a unique "de-wall" technology for its Ganoderma lucidum spore powder, significantly enhancing the efficacy and nutritional content compared to conventional products [23][36]. Financial Projections - Revenue is projected to grow from 784 million in 2023 to 1,078 million by 2026, with year-on-year growth rates of -5.4%, 10.6%, 11.4%, and 11.5% respectively [4][26]. - Net profit attributable to the parent company is expected to increase from 254 million in 2023 to 376 million in 2026, with growth rates of -8.4%, 12.1%, 16.3%, and 13.4% respectively [4][26]. - The gross margin is forecasted to improve from 82.7% in 2023 to 84.8% in 2026 [4][26]. Product and Market Strategy - The company categorizes its products into four types: "Monarch" products (core competitive products), "Minister" products (sub-brands), "Assistant" products (tactical products), and "Envoy" products (supplementary products) [1]. - The marketing strategy includes a combination of direct sales and distribution, as well as online and offline integration, with a focus on price control [1][21]. - The company has established eight standardized planting bases and focuses on the cultivation and processing of over twenty types of traditional Chinese medicinal materials [21][31]. Research and Development - The company has a robust R&D team comprising 141 members, with 28 external experts, including 9 academicians, focusing on the development of proprietary high-yield varieties and quality control systems [22][36]. - The company has led or participated in the formulation of 93 various traditional Chinese medicine standards, including ISO international standards for Ganoderma lucidum and Dendrobium [22][36].

证券研究报告 2024 年 7 月 19 日 湘财证券研究所 行业研究 公用事业行业数据点评 6 月电力生产稳健,水电发电量增长加速 ——2024 年 6 月发电量数据点评 相关研究: 核心要点: ❑ 事件 7 月 15 日,国家统计局发布 2024 年 6 月份能源生产情况。 ❑ 6 月电力生产稳健,水电发电量增长加速 | --- | --- | |------------------|-----------------------------------| | | 《发电行业碳配额方案发布,延续适度 | | 收紧趋势》 | 2024.07.09 | | | 《国家绿证核发交易系统启用,绿电交 | | 易市场有望扩容》 | 2024.07.01 | 行业评级:增持 近十二个月行业表现 | --- | --- | --- | --- | |----------|--------|--------|----------| | % | 1 个月 | 3 个月 | 12 个月 | | 相对收益 | 1 | 5 | 13 | | 绝对收益 | 2 | 4 | 5 | | | | | 300 相比 | 分析师:孙菲 证 ...

证券研究报告 2024 年 07 月 16 日 湘财证券研究所 行业研究 医疗耗材行业周报 耗材板块反转上行,关注近期业绩预告情况 相关研究: 核心要点: | --- | --- | |-------------------------------|------------| | 1.《国家集采持续推进,关注业绩 | | | 稳定性高的耗材个股》 | 2024.06.19 | | 2.《医疗行业利好政策再出台,板 | | | 块基本面边际向好》 | 2024.07.10 | 行业评级:增持 近十二个月行业表现 10.00% -40.00% 沪深300 医疗耗材 | --- | --- | --- | --- | |----------|--------|--------|----------| | % | 1 个月 | 3 个月 | 12 个月 | | 相对收益 | -2 | -3 | -12 | | 绝对收益 | -1 | -4 | -23 | | | | | 300 相比 | 分析师:聂孟依 证书编号:S0500524040001 Tel:(8621) 50299667 Email:nmy06967@xc ...